• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Basic Materials·002581.SZ
Share

Shandong Sinobioway Biomedicine Co., Ltd. Stocks

CN¥ 3.93Last Updated 16.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 321.30M

CN¥ 3.93
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shandong Sinobioway Biomedicine Co., Ltd., headquartered in Zibo, China, is a key producer and supplier of various chemical compounds, including trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, and ethyl formate. The company also manufactures general nerve growth factor and alfaron. Its pharmaceutical offerings further encompass NOBEX, which is a murine nerve growth factor delivered via injection; Anferon, a human recombinant interferon alpha 2b injection; and Jaferon, a human recombinant interferon alpha 2b formulated as a spray. Beyond these, the company provides a diverse portfolio of vaccines such as Healive, an inactivated vaccine for hepatitis A; Bilive, a combined vaccine targeting both hepatitis A and B; Panflu, designed for pandemic influenza; Anflu, a preservative-free influenza virus vaccine; and Panflu.1, specifically for Type A H1N1 influenza, among other related products. Established in 2000, its market extends internationally, with products being exported to roughly 20 nations and territories across Europe and the United States.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 13:00

"Weeks, not months": The IEA warned of the threat of a global crisis over the Strait of Hormuz

16.07.2026 11:30

Strive has been paying dividends every day for a month now. What risks does the company face?

16.07.2026 10:45

Samsung and SK Hynix shares plummeted ahead of TSMC's earnings report. The market is waiting for signals regarding AI

16.07.2026 10:30

Morning Roundup: New Strikes on Iran, Anthropic Heads Toward an IPO, and a Sell-Off in Asia

16.07.2026 09:30

"Market Leaders Face a Test of Resilience": Goldman Explains How to Protect Your Portfolio

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026